Rosefinch Tetrahedral Eye Soothing Gel: An Innovative Fusion of Nanotechnology and Botanical Extracts for a Renewed Eye Care Experience

In today’s digital age, eye fatigue—manifesting as dryness, redness, and swelling—has become a pervasive global health challenge, silently affecting people of all ages. According to the 2024 China Eye Health Industry Research Report, nearly 30% of China’s population experiences ocular discomfort. With the accelerating pace of population aging, age-related functional decline has significantly increased eye health issues among the elderly. Meanwhile, prolonged screen use reduces blinking frequency and accelerates tear evaporation, while environmental factors such as air conditioning, heating, and pollution further harm ocular surface health. As a result, the number of people experiencing eye discomfort is rapidly rising. Against this backdrop, the market for eye-soothing products has expanded, yet existing options remain limited in effectiveness—ranging from artificial tears that provide only 1–5 minutes of temporary relief to therapies that require 1–6 months before any noticeable improvement.

Current market products show clear limitations. Sodium hyaluronate eye drops, for example, offer quick but short-lived lubrication and fail to address the underlying causes of discomfort. Cyclosporin A, an immunomodulator, requires long treatment cycles of up to six months and often induces ocular irritation or other side effects. Many multi-dose formulations contain preservatives to prevent microbial contamination, yet long-term use may lead to fibrosis, meibomian gland dysfunction, and impaired tear secretion. Physical interventions such as intense pulsed light (IPL) therapy may provide improvement but demand repeated sessions at high cost, creating significant financial burdens. Overall, mainstream therapies are either too slow, associated with side effects, or require frequent application, while rarely resolving the root causes of eye fatigue and discomfort.

Rosefinch Tetrahedral Eye Soothing Gel offers a breakthrough solution. By uniquely combining tetrahedral framework nucleic acids (tFNAs) with botanical actives, it pioneers a sophisticated integration of nanomaterials and plant extracts. Applied around the eyes instead of directly on the ocular surface, it avoids preservative-related risks. As a structurally stable and biocompatible nanocarrier, tFNAs stably load and protect botanical compounds against degradation. With an ultra-small size of 6–10 nm and excellent permeability, tFNAs penetrate the skin barrier and efficiently deliver active molecules to ocular epithelial cells, lacrimal glands, and surrounding tissues within about six hours, increasing bioavailability by 10–20 times.

Most users report relief from dryness and discomfort within just 10 minutes of application, with a refreshing sensation that greatly enhances user experience. For daily care, only 2–3 applications are required, with a lightweight, non-greasy texture that fits seamlessly into fast-paced lifestyles. The formula is free from added hormones and is gentle on the skin. All tFNA-based products developed by Yunhai Bio undergo rigorous third-party safety evaluations—including cytotoxicity and genotoxicity testing—ensuring reliable safety for long-term use.

As a leader in the field of framework nucleic acids, Yunhai Bio brings top-tier scientific expertise. Supported by the National Center for Translational Medicine at Shanghai Jiao Tong University and the State Key Laboratory of Oral Diseases at Sichuan University, under the leadership of Professor Yunfeng Lin, the product’s development is grounded in cutting-edge research. Professor Lin’s team has conducted extensive studies on ocular applications of tFNAs, including corneal repair, glaucoma neuroprotection, retinal disease therapies, and ocular tumor inhibition. In particular, their dry eye research has shown that tFNAs can alleviate symptoms by reducing reactive oxygen species (ROS), suppressing inflammatory mediators such as MMP9 and IL-6, and modulating the cGAS–STING pathway, while promoting corneal epithelial healing, restoring goblet cell function, and enhancing tear secretion.

Professor Delun Luo, President of Yunhai Bio, has decades of experience in ophthalmology. A former consultant at the Ophthalmology Institute of Shanghai Jiao Tong University, he has overseen more than 20 Class I new drug projects, including leading the full development of Conbercept Ophthalmic Injection, which has achieved cumulative sales exceeding RMB 10 billion. His expertise and leadership have greatly advanced ophthalmic drug innovation.

In addition, Yunhai Bio has established deep collaborations with 12 leading institutions, including Zhongshan Ophthalmic Center, West China Hospital, Sichuan Provincial People’s Hospital, and the General Hospital of the Central Theater Command. These projects explore tFNA-miR22 for retinal ischemia-reperfusion injury, BIRDS22 therapy for pathological retinal neovascularization, tFNA-saRNA for oxidative stress-related retinal damage, and other multidimensional applications of tFNAs in ophthalmology. Together, these collaborations have produced 18 SCI-indexed publications, reflecting the company’s strong research foundation and significant academic contributions.

With its innovative technology, remarkable efficacy, and robust scientific background, Rosefinch Tetrahedral Eye Soothing Gel demonstrates vast potential and a bright future in the ophthalmic health market. We warmly welcome distributors, retailers, healthcare institutions, and wellness platforms to join us in promoting this pioneering product—bringing relief to millions suffering from ocular discomfort while advancing the global eye health industry.